Hi there!
We track 52,000+ AI startups and surface hidden job opportunities that never appear on LinkedIn. Tell us what you're looking for, our AI agent does the searching. It's free and you sign up using Google. Go explore!
bit.bio
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our…
bit.bio
bit.bio is an award-winning human synthetic biology company - our mission: coding cells for novel cures. We have developed an end-to-end platform for the creation of any human cell type. With our…
TL;DR
Core tech: opti-ox deterministic cell programming
Product focus: ioCells research products and txCells therapeutics pipeline
Founded: 2016 (Cambridge, UK)
Recent funding: $50M Series C (Jan 2026)
Employee count: 174
Company Overview
Problem Domain
Human cell sourcing variability and scalability for research, drug discovery and cell therapy development.
Founded
2016
Industry
Biotechnology Research
Tech Stack
Funding Track Record
$103 million
First close reported at $103M with participation from institutional and strategic investors
$30 million
Company announcement of $30M financing led by M&G Investments
$50 million
Series C announced and closed Jan 9, 2026
$41.5 million
Investor Signal
“M&G Investments as repeat lead/participant alongside institutional investors such as Arch Venture Partners, Foresite Capital and others”
